NS-018 + Best Available Therapy
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Myelofibrosis
Conditions
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Trial Timeline
Jan 31, 2023 → May 16, 2024
NCT ID
NCT04854096About NS-018 + Best Available Therapy
NS-018 + Best Available Therapy is a phase 2 stage product being developed by Nippon Shinyaku for Primary Myelofibrosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04854096. Target conditions include Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis.
What happened to similar drugs?
20 of 20 similar drugs in Primary Myelofibrosis were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04854096 | Phase 2 | Terminated |
Competing Products
20 competing products in Primary Myelofibrosis